Polatuzumab vedotin and obinutuzumab combination in octogenarians with B-cell non-Hodgkin lymphoma

The outcomes of elderly patients with lymphoma are poor. There is scarcity of data on outcomes of chemotherapy-free regimens in patients older than 80 years with a B-cell lymphoma. We report three octogenarians with B-cell NHL and the efficacy and safety of a nonchemotherapy regimen using a lower dose of polatuzumab vedotin and anti-CD20 monoclonal antibody. No infusion-related adverse events were noted. No patient developed neutropenia. Peripheral neuropathy was grade 2 in all cases. Recurrent UTI were a concern in two patients. After a median of 6 cycles (range 1-6) of polatuzumab therapy, all three patients had achieved CR. One patient was lost to follow-up and succumbed to a multidrug-resistant gram-negative UTI. One patient relapsed at 13 months and other is doing well in remission at 15 months.